NASH患者外周血单个核细胞TXNIP/NLRP3水平变化及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2022.06.016

摘要/Abstract

摘要： 目的探讨非酒精性脂肪性肝炎(NASH)患者外周血单个核细胞(PBMCs)硫氧还蛋白互作蛋白(TXNIP)/NOD样受体家族含pyrin结构域蛋白3(NLRP3)水平变化及其临床意义。方法 2019年1月～2021年1月我院收治的150例NASH患者和同期体检的单纯性脂肪肝患者45例,取外周血分离PBMCs,并检测TXNIP/NLRP3 mRNA。对NASH患者行两次肝穿刺活检,将肝组织病变程度分为轻度、中度和重度及进展和无进展组。结果 NASH患者血清ALT和AST水平分别为(72.2±6.9)U/L和(61.8±5.1)U/L,显著高于单纯性脂肪肝组【分别为(33.4±4.0)U/L和(31.3±3.1)U/L,P＜0.05】;NASH组PBMCs TXNIP mRNA、NLRP3 mRNA和TXNIP/NLRP3比值分别为(1.9±0.1)、(1.5±0.1)和(1.3±0.1),显著高于单纯性脂肪肝组【分别为(0.7±0.1)、(0.6±0.1)和(1.1±0.1),P＜0.05】;33例重度NASH组PBMCs TXNIP mRNA、NLRP3 mRNA和TXNIP/NLRP3比值分别为(2.4±0.2)、(1.9±0.2)和(1.6±0.1),显著高于49例轻度组【分别为(1.5±0.1)、(1.2±0.1)和(1.0±0.1),P＜0.05】或68例中度组【分别为(2.0±0.2)、(1.5±0.1)和(1.4±0.1),P＜0.05】;31例进展期NASH组PBMCs TXNIP mRNA、NLRP3 mRNA和TXNIP/NLRP3比值分别为(2.1±0.2)、(1.7±0.2)和(1.5±0.1),显著高于119例无进展组【分别为(1.8±0.1)、(1.4±0.1)和(1.2±0.1),P＜0.05】。结论 NASH患者PBMCs TXNIP/NLRP3基因水平显著升高,与肝功能损害程度明显存在某种关系。积极监测患者PBMCs这些基因的动态变化可能对评估病情和疾病转归有重要的意义,值得深入研究。

关键词: 非酒精性脂肪性肝炎, 硫氧还蛋白互作蛋白, NOD样受体家族含pyrin结构域蛋白3, 外周血单个核细胞, 进展期

Abstract: Objective The aim of this study was to explore the implications of peripheral blood mononuclear lymphocyte (PBMC) thioredoxin-interacting protein (TXNIP)/nod-like receptor family pyrin domain-containing protein 3 (NLRP3) in patients with nonalcoholic steatohepatitis (NASH). Methods A total of 150 patients with NASH and 45 persons with simple fatty liver (SFL) were recruited in our hospital between January 2019 and January 2021, and all had their PBMCs being separated to detect the TXNIP/NLRP3 mRNA. All patients with NASH had liver biopsies at presentation for determination of liver tissues injury degrees as mild, moderate and severe, and had a second time liver biopsies a year after recruitment as for determination of progressive or non-progressive diseases. Results Serum ALT and AST levels in patients with NASH were (72.2±6.9)U/L and (61.8±5.1)U/L, both significantly higher than [(33.4±4.0)U/L and (31.3±3.1)U/L, respectively, P＜0.05] in patients with SFL; the PBMCs TXNIP mRNA, NLRP3 mRNA and the ratio of TXNIP/NLRP3 in patients with NASH were (1.9±0.1), (1.5±0.1) and (1.3±0.1), all significantly higher than [(0.7±0.1), (0.6±0.1) and (1.1±0.1), respectively, P＜0.05] in patients with SFL; the PBMCs TXNIP mRNA, NLRP3 mRNA and the ratio of TXNIP/NLRP3 in 33 patients with severe NASH were (2.4±0.2), (1.9±0.2) and (1.6±0.1), significantly higher than [(1.5±0.1), (1.2±0.1) and (1.0±0.1), respectively, P＜0.05] in 49 patients with mild NASH or [(2.0±0.2), (1.5±0.1) and (1.4±0.1), respectively, P＜0.05] in 68 patients with moderate NASH; the PBMCs TXNIP mRNA, NLRP3 mRNA and the ratio of TXNIP/NLRP3 in 31 patients with progressive NASH were (2.1±0.2), (1.7±0.2) and (1.5±0.1), all significantly higher than [(1.8±0.1), (1.4±0.1) and (1.2±0.1), respectively, P＜0.05] in 119 patients without progressive NASH. Conclusion The PBMC TXNIP/NLRP3 mRNA in patients with NASH significantly increase, seemingly have some correlation to the liver tissue injuries, and needs further investigation.

Key words: Nonalcoholic steatohepatitis, Thioredoxin-interacting protein, Nod-like receptor family pyrin domain-containing protein 3, Peripheral blood mononuclear lymphocytes, Progression

张斌, 王依屹, 石磊. NASH患者外周血单个核细胞TXNIP/NLRP3水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(6): 820-823.

Zhang Bin, Wang Yiyi, Shi Lei. Implications of peripheral blood mononuclear lymphocyte TXNIP/NLRP3 in patients with nonalcoholic steatohepatitis[J]. Journal of Practical Hepatology, 2022, 25(6): 820-823.

参考文献

[1] 范建高,曾静. 非酒精性脂肪性肝病的流行现状与危害. 中华消化杂志,2020,40(9):10-13.
[2] Jing L,Qian C,Jing Y, et al. IFN-γ contributes to the hepatic inflammation in HFD-induced nonalcoholic steatohepatitis by STAT1β/TLR2 signaling pathway. Mol Immunol,2021,134(18):118-128.
[3] 金虎,江克清,钟伏弟,等. 非酒精性脂肪性肝炎治疗研究进展. 中华实验外科杂志, 2021,38(10):2055-2060.
[4] Yin Y,Liu H,Zheng Z ,et al. Genistein can ameliorate hepatic inflammatory reaction in nonalcoholic steatohepatitis rats. Biomed Pharmacot,2019,111(29):1290-1296.
[5] 阮雄中,陈压西. 代谢性炎症与非酒精性脂肪性肝病的发生与发展. 中华消化杂志, 2020,40(9):581-584.
[6] Bai R,Xu Y,Qin G, et al. Repression of TXNIP–NLRP3 axis restores intestinal barrier function via inhibition of myeloperoxidase activity and oxidative stress in nonalcoholic steatohepatitis. J Cell Physiol,2019,234(5):7524-7538.
[7] 饶紫兰,陈聪杰,胡俊,等. NOD样受体家族3基因敲除对改善非酒精性脂肪性肝炎小鼠肝损伤及脂代谢的影响. 中国临床药理学杂志, 2021,37(16):2217-2220.
[8] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年1月修订). 中华内科杂志,2010,49(3):275-278.
[9] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师煳旨肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版). 中华肝脏病杂志,2018, 26(3):195-203.
[10] Sun G,Zhao X,Li M ,et al. CD4 derived double negative T cells prevent the development and progression of nonalcoholic steatohepatitis. Nature Commun, 2021,12(1):650-652.
[11] 方菊梅,张万里,陈怡发,等. 非酒精性脂肪性肝炎患者血清sCD163和IL-1βmRNA水平变化及其临床意义探讨. 实用肝脏病杂志, 2020,23(3):368-371.
[12] 陈丽丽, 符茂雄, 刘正金,等. 非酒精性脂肪性肝炎患者血清成纤维细胞生长因子-21和脂联素水平变化及其临床意义探讨. 实用肝脏病杂志, 2020, 23(5):658-661.
[13] Slater T F,Cheeseman K H,Benedetto C,et al. Studies on the hyperplasia (regeneration) of the rat liver following partial hepatectomy. Changes in lipid peroxidation and general biochemical aspects. Biochem J, 2019, 265(1):51-59.
[14] Liu Y,Li Y P,Xiao L M,et al. Extracellular vesicles derived from M2 microglia reduce ischemic brain injury through microRNA-135a-5p/TXNIP/NLRP3 axis. Lab Invest, 2021,101(7):1-14.
[15] 万小雨,曾俊豪,张婉怡,等. 非酒精性脂肪性肝炎小鼠模型的建立. 中国免疫学杂志, 2020,36(16):1925-1930.
[16] Zhu L Y,Liu C,Li Z R,et al. NLRP3 deficiency did not attenuate NASH development under high fat calorie diet plus high fructose and glucose in drinking water. Lab Invest, 2021,101(5):588-599.
[17] Cao G,Nan J,Hu Y,et al. Ruscogenin attenuates cerebral ischemia-induced blood-brain barrier dysfunction by suppressing TXNIP/NLRP3 inflammasome activation and the MAPK pathway. Int J Mol Ences, 2016,17(9):1418-1419.
[18] Loomba R,Mohseni R,Lucas K J,et al. TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial. Gastroenterology, 2021, 161(5):1475-1486.
[19] Huang H M, SJ Fan, Zhou X R,et al. Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis. Acta Pharmacol Sin, 2021,43(4):941-953.
[20] Glass O, Henao R, Patel K,et al. Serum interleukin-8, osteopontin, and monocyte chemoattractant protein 1 are associated with hepatic fibrosis in patients with nonalcoholic fatty liverdDisease. Hepatol Commun, 2018, 2(11):1344-1355.

NASH患者外周血单个核细胞TXNIP/NLRP3水平变化及其临床意义探讨^*

Implications of peripheral blood mononuclear lymphocyte TXNIP/NLRP3 in patients with nonalcoholic steatohepatitis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王晴, 张利莉. 当2型糖尿病遇上非酒精性脂肪性肝病:1+1＞2 ？[J]. 实用肝脏病杂志, 2022, 25(4): 460-463.
[2]	张羿, 尹刚, 赵艳萍. NASH患者外周血乏氧诱导因子1a-反义RNA 1和自噬基因Beclin1变化及其临床意义^*[J]. 实用肝脏病杂志, 2022, 25(4): 517-520.
[3]	韩冰, 涂传涛. NASH患者肝巨噬细胞在肝纤维化形成过程中的作用及其临床转化研究进展^*[J]. 实用肝脏病杂志, 2022, 25(3): 309-313.
[4]	王琳, 林雪松, 丁楠. 非酒精性单纯性脂肪肝与非酒精性脂肪性肝炎患者血清脂质组学比较^*[J]. 实用肝脏病杂志, 2022, 25(2): 215-218.
[5]	许政衡, 黄勇, 柯海霞, 李南, 马乙云. 慢性乙型肝炎患者外周血单个核细胞Galectin-3基因水平对聚乙二醇干扰素α治疗应答的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 811-814.
[6]	闻啟富, 马利军, 王晓亮. 非酒精性脂肪性肝炎患者血清CK18和FGF-21水平变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(6): 835-838.
[7]	王子璇, 王梦雨, 李经纬, 杨蕊旭, 曾静, 潘勤, 范建高. 门冬氨酸鸟氨酸对非酒精性脂肪性肝炎合并肌少症性肥胖小鼠的保护作用^*[J]. 实用肝脏病杂志, 2021, 24(5): 657-660.
[8]	李妍, 陆伦根, 蔡晓波. HIF-1α对非酒精性脂肪性肝病小鼠肝组织的影响^*[J]. 实用肝脏病杂志, 2021, 24(5): 665-668.
[9]	吴丽蒙, 龚翔, 张燕. 非酒精性脂肪性肝炎患者外周血跨膜蛋白6超家族成员2基因表达与心血管疾病的关系^*[J]. 实用肝脏病杂志, 2021, 24(4): 504-507.
[10]	袁平戈, 陈文雯. 非酒精性脂肪性肝炎新药研发临床思考[J]. 实用肝脏病杂志, 2021, 24(3): 305-307.
[11]	杨振辉, 古宝欢, 戴小灵. 非酒精性脂肪性肝炎患者肝脏受控衰减参数的变化[J]. 实用肝脏病杂志, 2021, 24(2): 212-215.
[12]	许超, 王森钰, 罗援烨, 陈王丽, 周芸, 盛以泉, 郭满盈. 肝细胞癌患者PBMCs TLR 2/4表达和小肠细菌过度生长对TACE术后生存期的影响[J]. 实用肝脏病杂志, 2021, 24(2): 248-251.
[13]	吴刚, 陈训军, 张万里, 李芬. 二氢姜黄素体外处理BRL-3A细胞对细胞凋亡通路的影响[J]. 实用肝脏病杂志, 2020, 23(5): 622-625.
[14]	王雨, 王楠, 刘媛媛, 李永勤, 王巧侠, 付建军. 草质素对非酒精性脂肪性肝炎大鼠肝脂肪变和肝内氧化应激的影响[J]. 实用肝脏病杂志, 2020, 23(5): 626-629.
[15]	陈丽丽, 符茂雄, 刘正金, 方其超, 张茂. 非酒精性脂肪性肝炎患者血清成纤维细胞生长因子-21和脂联素水平变化及其临床意义探讨[J]. 实用肝脏病杂志, 2020, 23(5): 658-661.